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Research
U.S. production and use of polychlorinated
biphenyls (PCBs) ended in 1977 (Smith and
Brown 1987). Concern continues about the
persistence of PCBs in the environment and
potential human health risks. Several strains of
rats exposed to PCBs had preneoplastic
changes of the biliary tract, intestine, and
stomach (Morgan et al. 1981; National Cancer
Institute 1978) and increased incidence of liver
tumors (Carpenter 2000; Kimbrough et al.
1975). Liver toxicity and hepatocellular neo-
plasm incidence differed between PCB mix-
tures, were more severe in females than in
males, and increased with dose in females
(Mayes et al. 1998).
The International Agency for Research on
Cancer (IARC 1987) concluded that there is
sufﬁcient evidence of carcinogenicity of PCBs
in animals but limited evidence in humans.
Studies of PCB-exposed workers have gener-
ally found excesses for several cancer sites, but
many were limited by sample size, impreci-
sion in measuring PCB exposure, and/or
inability to control for other risk factors and
confounders (Carpenter 2000; Faroon et al.
2001).
The mortality of 2,588 workers considered
highly exposed to PCBs at two electrical
capacitor plants in New York (plant 1) and
Massachusetts (plant 2) was initially studied
through 1975 (Brown and Jones 1981) and
later updated through 1982 (Brown 1987) and
1998 (Prince et al. 2006). In the current study
we expanded this cohort to include all employ-
ees who worked ≥ 90 days, and we ascertained
their vital status through 1998. We used a
semiquantitative job-exposure matrix (JEM) to
estimate cumulative PCB exposure. 
Our goal was to investigate previously
reported mortality excesses for cancers of the
biliary passages, liver, and gallbladder (hence-
forth, liver cancer) and rectum (Brown 1987).
Other a priori outcomes of interest included
all-cancer mortality (Bertazzi et al. 1987),
non-Hodgkin lymphoma (NHL) (Rothman
et al. 1997; Hardell et al. 2001), breast cancer
(Falck et al. 1992), melanoma and brain can-
cer (Loomis et al. 1997; Sinks et al. 1992),
prostate cancer (Charles et al. 2003; Ritchie
et al. 2003) and stomach and intestinal cancer
(Mallin et al. 2004). 
Methods
The expanded cohort included all workers with
≥ 90 days of employment at plant 1 between
1 January 1946 and 30 June 1977, or at plant 2
between 1 January 1939 and 29 March 1976.
For plant 1, work histories indicated whether
jobs were salaried or hourly positions; those for
plant 2 did not. Based on an examination of
job titles, all plant 2 workers were considered
hourly. Salaried workers at plant 1 were
included in the expanded cohort because many
had both hourly and salaried experience and
may have worked alongside hourly employees.
In analyses restricted to plant 1 hourly workers,
we classiﬁed employees as “hourly” if they had
been employed ≥ 90 days in nonsalaried jobs.
Employment records provided Social Security
numbers, demographic information, and
work histories. For plant 1, we used Internal
Revenue Service Employer’s Quarterly Earning
Reports (form 941) and pension rosters to ver-
ify completeness of ascertainment. Plant 1
cohort members included workers studied by
Kimbrough et al. (1999, 2003). 
Demographic information (race, sex,
birth date) was corrected or updated based on
data from 4,300 interviews for a cohort breast
cancer incidence study. Race was routinely
veriﬁed and/or updated for deceased workers
based on death certificates. Employment
records did not include race information.
Many plant 2 workers were possibly of mixed
ethnic origin (Cape Verdean). Workers with
only employment records were assigned
“unknown” race, whereas workers for whom
we had death certificates or interview data
were assigned distinct race codes of white,
black, Asian, Hispanic, or American Indian.
Workers coded as black, Asian, or American
Indian were assumed to be nonwhite; based
on area demographics, all other workers were
assumed to be white. 
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BACKGROUND: We expanded an existing cohort of workers (n = 2,588) considered highly exposed
to polychlorinated biphenyls (PCBs) at two capacitor manufacturing plants to include all workers
with at least 90 days of potential PCB exposure during 1939–1977 (n = 14,458). Causes of death
of a priori interest included liver and rectal cancers, previously reported for the original cohort, and
non-Hodgkin lymphoma (NHL), melanoma, and breast, brain, intestine, stomach, and prostate
cancers, based on other studies. 
METHODS: We ascertained vital status of the workers through 1998, and cumulative PCB exposure
was estimated using a new job exposure matrix. Analyses employed standardized mortality ratios
(SMRs; U.S., state, and county referents) and Poisson regression modeling. 
RESULTS: Mortality from NHL, melanoma, and rectal, breast, and brain cancers were neither in
excess nor associated with cumulative exposure. Mortality was not elevated for liver cancer
[21 deaths; SMR 0.89; 95% conﬁdence interval (CI), 0.55–1.36], but increased with cumulative
exposure (trend p-value = 0.071). Among men, stomach cancer mortality was elevated (24 deaths;
SMR 1.53; 95% CI, 0.98–2.28) and increased with cumulative exposure (trend p-value = 0.039).
Among women, intestinal cancer mortality was elevated (67 deaths; SMR 1.31; 95% CI,
1.02–1.66), especially in higher cumulative exposure categories, but without a clear trend. Prostate
cancer mortality, which was not elevated (34 deaths; SMR 1.04; 95% CI, 0.72–1.45), increased
with cumulative exposure (trend p-value = 0.0001).
CONCLUSIONS: This study corroborates previous studies showing increased liver cancer mortality,
but we cannot clearly associate rectal, stomach, and intestinal cancers with PCB exposure. This is
the ﬁrst PCB cohort showing a strong exposure–response relationship for prostate cancer mortality. 
KEY WORDS: cancer, electrical capacitor manufacturing, liver cancer, mortality, occupational expo-
sure, PCBs, polychlorinated biphenyls, prostate cancer. Environ Health Perspect 114:1508–1514
(2006). doi:10.1289/ehp.9175 available via http://dx.doi.org/ [Online 22 June 2006]This study added 11,870 workers to the
original cohort of 2,588 (Prince et al.
2006), and ascertained vital status through
31 December 1998, by linking to the Social
Security Administration, the Internal Revenue
Service, the National Death Index (NDI;
National Center for Health Statistics 1999),
the U.S. Postal Service, and credit bureaus.
Causes of death were obtained from NDI Plus
or coded by a qualiﬁed nosologist from death
certificates according to the International
Classiﬁcation of Diseases (ICD) revision in effect
at the time of death [data are presented accord-
ing to the ninth revision (ICD-9; World
Health Organization 1977)]. Because the NDI
excludes deaths before 1979, workers lost to
follow-up before 1979 were classiﬁed as “vital
status unknown” and considered alive until the
date last observed. Workers not lost to follow-
up before 1979 and not reported as deceased
were considered alive until the study end date.
This study was approved by the National
Institute for Occupational Safety and Health
(NIOSH) Human Subjects Review Board. 
Commercial PCB mixes, 41–54% chlorine
(Brown and Jones 1981), were used at both
plants, with less chlorinated varieties used more
recently. At any given time, more than one mix
likely was in use. NIOSH conducted exposure
surveys in spring 1977. Time-weighted average
air samples ranged from 24–476 µg/m3 at
plant 1 and 50–1,260 µg/m3 at plant 2 (Brown
and Jones 1981). 
We developed plant-speciﬁc semiquantita-
tive JEMs using job descriptions, production
factors, process information, PCB usage eras,
industrial hygiene air sampling data, and expo-
sure determinants such as proximity to bulk
PCB sources, process temperature, frequency
and duration of tasks involving contact with
PCB oil, and other chemical exposures (Nilsen
et al. 2004, 2005). Jobs were assessed sepa-
rately for potential inhalation and dermal
exposures. We used plant-speciﬁc air concen-
trations to assign values to the qualitative
(high, medium, low, background) inhalation
and dermal exposure ratings, with dermal
exposure values unitless. A combined JEM
averaged inhalation and dermal exposure scores
because workers typically were exposed by both
routes. Like its dermal component, this com-
bined metric is unitless; cumulative exposure is
a number of unit-days of exposure. 
We evaluated concomitant exposure to
other chemicals. Trichloroethylene (TCE)
has been associated with liver cancer risk
(Wartenberg et al. 2000). Only workers who
cleaned capacitors or performed degreasing
had consistently high TCE exposures. Data
suggest that TCE degreasing occurred during
most years of PCB usage at plant 1 but ended
by the mid-1970s. Plant 2 used TCE through-
out the period of PCB exposure, but pre-1950
work histories lacked the speciﬁcity needed to
identify jobs with potential TCE exposure. In
the mid-1970s, TCE levels at both plants were
generally below the Occupational Safety and
Health Administration permissible exposure
limit of 100 ppm [Agency for Toxic Substances
and Disease Registry (ATSDR) 2001; Brown
and Jones 1981]. Some workers at both plants
also had exposures to lead and zinc during sol-
dering; plant 1 workers had exposures to
toluene and methyl butyl ketone during paint-
ing, and to aluminum and iron during welding
(Brown and Jones 1981). 
We used the NIOSH personal computer
life table analysis system (Steenland et al. 1998)
to compute person-years at risk (PYAR),
expected numbers of deaths, and standardized
mortality ratios (SMRs) based on U.S. and
appropriate state and county rates. PYAR accu-
mulation started on the 90th day of employ-
ment during the PCB exposure period or the
date the rate ﬁles began, whichever was later;
PYAR ended at death, date lost to follow-up, or
the study end date (31 December 1998),
whichever was earliest. In addition to analysis of
underlying cause of death, all causes listed on
the death certiﬁcates were analyzed using multi-
ple cause mortality methods (Steenland et al.
1992). For myeloma, NHL, and melanoma,
U.S. rate ﬁles begin on 1 January 1960; multi-
ple cause and state and county death rate ﬁles
also begin on this date. For other causes of
death, U.S. rate ﬁles begin on 1 January 1940. 
For tests of trend, we used quartiles of
cumulative exposure among deceased workers
(150, 620 and 2,300 unit-years) to stratify
observed deaths and PYAR. All deaths and all
cancer deaths were partitioned approximately
equally into these quartiles; speciﬁc cancers (i.e.,
liver and prostate) were not necessarily equally
partitioned. Trend tests were conducted for all
a priori outcomes and those found to be in
excess among long-term workers [≥ 10 years
employment and ≥ 20 years time since first
exposure (TSFE)]. Internal comparisons used
multivariate Poisson regression modeling with
SAS 9 software (SAS Institute 2006) to calcu-
late rate ratios (RRs) for three higher exposure
categories relative to the lowest. Poisson regres-
sion models examining cumulative exposure
and mortality were adjusted for sex, age, and
calendar year. Cumulative exposure was lagged
for zero, 10, and 20 years. Categories of age,
calendar year, or cumulative exposure were
combined as necessary to eliminate categories
with zero observed deaths. Workers with
unknown job information (16 in plant 1 and
470 in plant 2) were excluded from exposure–
response analyses. 
To eliminate possible confounding due to
concomitant TCE exposure, supplemental
analyses for certain cancers excluded workers
who ever performed degreasing. A sensitivity
analysis categorized Portuguese-surnamed
workers (a surrogate for Cape Verdean ances-
try) as nonwhite to determine if SMRs would
have changed if ethnicity were misclassified
(approximately 32% of plant 2 workers and
< 0.5% of plant 1 workers had Portuguese
surnames). 
Results
The employment criterion was met by 14,458
workers (Table 1). Loss to follow-up rates
were similar by sex across the two plants
(5–6%; results not shown). At plant 1, dura-
tion of employment was similar for males and
females (medians, 2.3 and 2.1 years, respec-
tively), but cumulative PCB exposure was gen-
erally higher among males than among
females (medians, 280 and 140 unit-years,
respectively); however, at plant 2, males gener-
ally worked fewer years than females (medians,
1.3 and 2.0 years, respectively), but cumula-
tive PCB exposure was similar for males and
females (medians, 340 and 360 unit-years,
respectively). Only 550 workers (4% overall;
7.4% in plant 1; 0.5% in plant 2) had known
TCE degreasing activities (lack of speciﬁcity in
pre-1950 job data may be responsible for the
smaller proportion in plant 2). At both plants,
91% of the cohort had ≥ 20 years TSFE and
83% of deaths and 88% of cancer deaths
occurred among workers with ≥ 20 years
TSFE. 
Table 2 describes the overall mortality
experience of the cohort, based on U.S. mor-
tality rates; results were similar using state and
county rates, except as noted below. Total
mortality was less than expected. 
Overall, no a priori outcome of interest
(i.e., all cancers; cancers of the rectum, liver,
intestine, stomach, breast, prostate, and
brain; melanoma; NHL) was significantly
elevated in the cohort. Melanoma mortality
was elevated among plant 1 workers. Stomach
cancer mortality among men and intestinal
cancer mortality among women were ele-
vated, (more elevated using U.S. referents,
less elevated using state and county referents.
Myeloma mortality, not of a priori interest,
was elevated primarily among men and
plant 1 workers. 
Chronic and unspeciﬁed bronchitis mor-
tality was elevated, primarily among women
and plant 1 workers. Mortality from “other
nervous system diseases” (Parkinson disease
and other neurodegenerative diseases) was ele-
vated among women. Ischemic heart disease
mortality was not reduced overall, and it was
higher among plant 2 workers.
Mental disorders, other diseases of the
heart (a category including cardiomyopathy
and congestive heart failure), and diseases of
the respiratory, digestive, and genitourinary
systems had lower than expected mortality.
Mortality from accidents, suicide, and homi-
cide was quite low using U.S. referent rates
but less so with state or county rates. 
Mortality and occupational PCB exposure
Environmental Health Perspectives • VOLUME 114 | NUMBER 10 | October 2006 1509SMRs for “long-term” employees were
elevated for total cancer in plant 2 [168
deaths; SMR, 1.13; 95% conﬁdence interval
(CI), 0.97–1.32], cancers of the rectum, liver,
stomach in men, breast, female genital organs,
and prostate; and chronic and unspecified
bronchitis, whereas SMRs similar to those of
the total cohort or reduced, were observed for
cancers of the intestine and brain, melanoma,
NHL, and myeloma (results not shown). 
Table 3 shows results of the internal expo-
sure–response analyses. For total cancer, RRs
increased with increasing exposure across lag-
ging categories; the trends for 0- and 10-year
lags were statistically significant, and the
20-year trend was of borderline statistical sig-
nificance. We observed a positive trend for
liver cancer SMRs with increasing cumulative
exposure. Liver cancer RRs in lagged analyses,
especially the 20-year lag, were suggestive of a
trend. This trend persisted in subsequent
analyses (results not shown) that excluded
either workers who were potentially exposed
to TCE or salaried workers. We did not
observe exposure–response trends across 
lagging categories for mortality from cancers
of the stomach, intestine, rectum, breast, and
brain; melanoma; NHL; and myeloma. 
Exposure–response analyses suggested a
positive association between stomach cancer
mortality and cumulative exposure. Among
men, positive trends with cumulative exposure
were statistically significant in the unlagged
and 10-year-lagged analyses. These trends per-
sisted in analyses that excluded either workers
who were potentially exposed to TCE or
salaried workers (results not shown). Mortality
from intestinal cancer was elevated relative to
the referent group, particularly among women;
however, trend tests for intestinal cancer
among women were not statistically signiﬁcant. 
We observed a positive trend for prostate
cancer mortality with increasing cumulative
exposure in internal analyses, whether lagging
for 0, 10, or 20 years. The trend was observed
consistently in subsequent analyses that exam-
ined multiple causes of death or excluded
either workers who were potentially exposed to
TCE or salaried workers (results not shown).
Mortality from female genital organ can-
cers—which was elevated among long-term
workers (results not shown) but has not been
reported in the literature as associated with
PCB exposure—was examined in internal
analyses (Table 3). There were suggestions of
trends in mortality with cumulative exposure
for cancers of other and unspecified parts of
the uterus and ovary, fallopian tube, and
broad ligament but not for cervical cancer
(results not shown). RRs for uterine cancer
were elevated but were highly unstable. RRs
for ovarian cancer were elevated, and the
trend tests became more pronounced with
increased lag period or exclusion of salaried
workers (results not shown). 
Discussion
The relationship between cumulative expo-
sure to PCBs and liver cancer mortality
reported here corroborates the study of the
most highly exposed workers in this cohort
(Prince et al. 2006), as well as other studies
(Bertazzi et al. 1987; Greenland et al. 1994;
Mallin et al. 2004). However, we found no
evidence that previously reported excesses of
rectal cancer in that subcohort were related to
PCB exposure (Brown 1987; Brown and
Jones 1981). For cumulative PCB exposure,
we also found a) an exposure–response rela-
tionship with overall cancer mortality; b)a
strong exposure–response relationship with
prostate cancer mortality; c) suggestive evi-
dence of an association with mortality from
myeloma, ovarian cancer, and stomach cancer
among men; and d) equivocal evidence for an
association with mortality from intestinal can-
cer among women. We found no signiﬁcant
mortality excesses in this cohort for NHL,
melanoma, or cancers of the brain and breast,
contrary to some studies (Falck et al. 1992;
Loomis et al. 1997; Rothman et al. 1997;
Ruder et al. 2006), but consistent with mor-
tality studies of plant 1 of this cohort
(Kimbrough et al. 1999, 2003). 
Associations between environmental or
occupational exposures and prostate cancer
have been reported in the literature (Hessel
et al. 2004; Zeegers et al. 2004), but less is
known about PCB effects. In a prostate cancer
case–control study, Ritchie et al. (2003)
reported a weak exposure response for lipid-
adjusted serum levels of PCB congener 180,
whereas in a nested case–control study of U.S.
electrical utility workers, Charles et al. (2003)
found that prostate mortality was not associ-
ated with frequency and duration of employ-
ment in PCB-exposed jobs, and only minor
elevations in risk were observed at the highest
PCB exposure levels. The present study pro-
vides the strongest evidence to date for an
association of prostate cancer with cumulative
PCB exposure in an occupational cohort. The
observed exposure–response relationship in
this study has biological plausibility if the
mechanism for PCB-induced prostate cancer
is related to disruption of estrogenic pathways
(Charles et al. 2003; Ritchie et al. 2003).
Further study of the association of prostate
cancer with PCB exposure will be conducted
in this cohort using cancer incidence data. 
Prince et al.
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Table 1. Characteristics of PCB-exposed workers employed ≥ 90 days.a
Characteristic Plant 1 Plant 2 Total
No. of workers 6,941 7,517 14,458
Sex/race, n (%)
Male/white 3,971 (57) 2,506 (33) 6,477 (45)
Male/nonwhite 4 (< 1) 16 (< 1)  20 (< 1)
Female/white 2,938 (42) 4,834 (64) 7,772 (54)
Female/nonwhite 28 (< 1) 161 (2) 189 (1)
Vital status as of 31 December 1998, n (%)
Deceased, cause of death known 1,514 (22) 1,760 (23) 3,274 (23)
Deceased, cause of death unknown 72 (1) 71 (1) 143 (1)
Alive 5,021 (72) 5,269 (70) 10,290 (71)
Unknown 334 (5) 417 (6) 751 (5)
Pay status, n (%) 
Hourly 5,244 (76) 7,517 (100) 12,761 (88)
Salaried 1,697 (24) 0 (0) 1,697 (12)
Duration of employment,b n (%)
Median (range), years 2.2 (0.25–31.5) 1.7 (0.25–37.0) 1.9 (0.25–37.0)
90 days to < 2 years 3,342 (48) 4,014 (53) 7,356 (51)
2–9 years 2,136 (31) 2,198 (29) 4,334 (30)
≥ 10 years 1,463 (21) 1,305 (17) 2,768 (19)
Cumulative exposurec (unit-years), n (%)
Unknown 16 (< 1) 470 (6) 486 (3)
< 150 2,985 (43) 2,092 (28) 5,077 (35)
150 to < 620 1,805 (26) 2,263 (30) 4,068 (28)
620 to < 2,300 1,264 (18) 1,414 (19) 2,678 (19)
≥ 2,300 871 (13) 1,278 (17) 2,149 (15)
Years since ﬁrst employment, n (%)
Median (range) 32.6 (0.25–53.0) 37.5 (0.25–60.0) 34.5 (0.26–60.0)
< 20 years 601 (9) 684 (9) 1,285 (9)
20–39 years 4,337 (62) 3,872 (52) 8,209 (57)
≥ 40 years 2,003 (29) 2,961 (39) 4,964 (34)
Years since last employment
Median (range) 26.7 (0–52.7) 31.7 (0–53.6) 29.4 (0.0–53.6)
Person-years at risk 227,131 268,992 496,123
aAll workers with at least 90 days of employment during the period when PCBs were in use, except those missing date of
birth (n = 52) or date of death (n = 1). bTime worked while PCBs were in use at the plants. cEstimated using the combined
inhalation–dermal job exposure matrix; 486 workers had “unknown” cumulative exposure because each had at least one
job with an unknown code.Mortality and occupational PCB exposure
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Table 2. Mortality among PCB-exposed workers employed ≥ 90 days, 1940–1998.a
Total cohort
Underlying cause of deathb All workers Male Female Plant 1 Plant 2
(ICD-9 code) Obs SMR 95% CI Obs SMR 95% CI Obs SMR 95% CI Obs SMR 95% CI Obs SMR 95% CI
All deaths 3,417 0.93** 0.90–0.96 1,674 0.88** 0.84–0.93 1,743 0.97 0.93–1.02 1,586 0.87** 0.83–0.92 1,831 0.98 0.94–1.03
All cancers (140–208) 1,015 1.00 0.94–1.06 438 0.95 0.86–1.04 577 1.04 0.96–1.13 473 0.95 0.87–1.04 542 1.04 0.96–1.13
MN of buccal cavity and pharynx  19 1.04 0.63–1.63 12 1.04 0.54–1.82 7 1.04 0.42–2.14 14 1.44 0.79–2.42 5 0.59 0.19–1.37
(140–149) 
MN of digestive organs and  242 1.05 0.92–1.19 109 0.97 0.79–1.16 133 1.13 0.95–1.34 114 1.00 0.83–1.20 128 1.10 0.92–1.30
peritoneum (150–159)
Esophagus (150) 17 0.99 0.57–1.58 12 0.98 0.51–1.71 5 1.00 0.32–2.34 6 0.63 0.23–1.37 11 1.43 0.71–2.56
Stomach (151) 31 1.13 0.77–1.60 24 1.53 0.98–2.28 7 0.59 0.24–1.22 12 0.86 0.45–1.51 19 1.40 0.84–2.19
Intestine, excluding rectum (152–153) 106 1.16 0.95–1.41 39 0.97 0.69–1.33 67 1.31* 1.02–1.66 53 1.21 0.90–1.58 53 1.12 0.84–1.47
Rectum (154) 21 1.14 0.70–1.74 8 0.86 0.37–1.69 13 1.42 0.75–2.43 11 1.20 0.60–2.15 10 1.07 0.51–1.96
Biliary passages, liver, and  21 0.89 0.55–1.36 7 0.63 0.25–1.30 14 1.12 0.61–1.87 9 0.78 0.36–1.48 12 0.99 0.51–1.73
gallbladder (155–156)
Pancreas (157) 44 0.91 0.66–1.22 18 0.79 0.47–1.25 26 1.02 0.67–1.50 21 0.89 0.55–1.35 23 0.94 0.59–1.41
MN respiratory system (160–165) 272 0.95 0.84–1.07 139 0.82* 0.69–0.97 133 1.15 0.96–1.36 133 0.88 0.73–1.04 139 1.04 0.87–1.23
Trachea, bronchus, and lung (162) 256 0.93 0.82–1.05 127 0.78** 0.65–0.93 129 1.15 0.96–1.36 125 0.86 0.71–1.02 131 1.02 0.85–1.21
MN of breast (174–175) 111 0.95 0.78–1.15 0 — — 111 0.96 0.79–1.15 39 0.91 0.65–1.24 72 0.98 0.77–1.23
MN of female genital organs (179–184) 75 1.06 0.84–1.33 NA NA NA 75 1.06 0.84–1.33 29 1.13 0.76–1.63 46 1.02 0.75–1.36
Cervix uteri (180) 22 1.29 0.81–1.95 NA NA NA 22 1.29 0.81–1.95 10 1.65 0.79–3.03 12 1.09 0.56–1.90
Other and unspeciﬁed parts of the  15 0.99 0.56–1.64 NA NA NA 15 0.99 0.56–1.64 6 1.11 0.41–2.42 9 0.93 0.42–1.76
uterus (179, 181–182)
Ovary, fallopian tube, and  35 0.96 0.67–1.34 NA NA NA 35 0.96 0.67–1.34 11 0.82 0.41–1.47 24 1.05 0.67–1.56
broad ligament (183)
MN of prostate (185) 34 1.04 0.72–1.45 34 1.04 0.72–1.45 NA NA NA 21 1.00 0.62–1.53 13 1.10 0.59–1.89
MN of kidney (189.0–189.2) 20 0.96 0.58–1.48 13 1.08 0.57–1.84 7 0.79 0.32–1.63 10 0.92 0.44–1.69 10 1.00 0.48–1.84
MN of bladder and other urinary organs  17 1.00 0.58–1.60 12 1.07 0.55–1.88 5 0.85 0.28–2.00 7 0.76 0.31–1.57 10 1.27 0.61–2.34
(188, 189.3–189.9)
MN of other and unspeciﬁed sites  125 0.98 0.82–1.17 72 1.17 0.92–1.48 53 0.81 0.61–1.06 63 1.00 0.77–1.28 62 0.97 0.74–1.24
(170–173, 190–199)
Melanoma (172) 19 1.26 0.76–1.97 14 1.66 0.91–2.79 5 0.75 0.24–1.75 14 1.79 0.98–3.00 5 0.69 0.22–1.61
Brain (191, 192) 23 0.79 0.50–1.19 15 1.04 0.58–1.72 8 0.55 0.23–1.07 11 0.76 0.38–1.36 12 0.82 0.43–1.44
Neoplasms of lymphatic and  99 1.05 0.85–1.28 46 1.00 0.73–1.33 53 1.10 0.82–1.44 42 0.90 0.65–1.21 57 1.20 0.91–1.55
hematopoietic tissue (200–208)
Leukemia and aleukemia (204–208) 34 0.96 0.66–1.34 13 0.73 0.39–1.24 21 1.19 0.74–1.82 14 0.79 0.43–1.33 20 1.12 0.68–1.72
NHL (200, 202) 35 0.98 0.68–1.36 16 0.95 0.54–1.54 19 1.01 0.61–1.58 12 0.68 0.35–1.18 23 1.28 0.81–1.92
Myeloma (203) 28 1.85** 1.23–2.67 16 2.31** 1.32–3.76 12 1.46 0.75–2.54 15 2.02* 1.13–3.34 13 1.68 0.89–2.87
Benign and unspeciﬁed neoplasms  9 0.63 0.29–1.19 2 0.35 0.04–1.25 7 0.82 0.33–1.68 2 0.30 0.04–1.09 7 0.91 0.36–1.87
(210–239)
Diabetes mellitus (250) 72 0.89 0.70–1.12 21 0.64* 0.40–0.98 51 1.06 0.79–1.40 32 0.85 0.58–1.20 40 0.93 0.66–1.26
Blood and blood-forming organ  17 1.31 0.76–2.10 10 1.77 0.85–3.26 7 0.95 0.38–1.96 8 1.30 0.56–2.57 9 1.31 0.60–2.50
diseases (280–289)
Mental, psychoneurotic, and  22 0.64* 0.40–0.96 6 0.34**0.13–0.75 16 0.94 0.53–1.52 10 0.59 0.28–1.08 12 0.68 0.35–1.19
personality disorders (290–319)
Multiple sclerosis (340) 6 0.93 0.34–2.03 3 1.46 0.30–4.27 3 0.68 0.14–2.00 2 0.69 0.08–2.49 4 1.13 0.31–2.88
Other nervous system diseases  61 1.16 0.88–1.48 15 0.64 0.36–1.05 46 1.57**1.15–2.10 25 0.98 0.64–1.45 36 1.32 0.92–1.82
(320–337, 341–389)
Heart diseases (390–398, 402, 404,  1,104 0.93* 0.87–0.98 619 0.92* 0.85–0.99 485 0.94 0.86–1.03 517 0.86**0.79–0.94 587 1.00 0.92–1.08
410–414, 420–429)
Ischemic heart disease (410–414) 861 0.97 0.90–1.03 492 0.93 0.85–1.01 369 1.02 0.92–1.13 399 0.87**0.79–0.96 462 1.07 0.97–1.17
Hypertension with heart disease  26 0.71 0.47–1.05 12 0.74 0.38–1.30 14 0.69 0.38–1.16 10 0.61 0.29–1.12 16 0.80 0.46–1.30
(402, 404)
Other heart diseases (420–423,  182 0.86* 0.74–0.99 95 0.89 0.72–1.09 87 0.82 0.66–1.02 92 0.88 0.71–1.08 90 0.84 0.68–1.03
425–428, 429.2–429.9)
Other circulatory system diseases  329 1.01 0.90–1.12 141 0.99 0.83–1.16 188 1.02 0.88–1.18 129 0.85 0.71–1.01 200 1.15 0.99–1.32
(401, 403, 405, 415–417, 430–459)
Respiratory system diseases (460–519) 220 0.83**0.73–0.95 106 0.80* 0.66–0.97 114 0.87 0.71–1.04 126 0.96 0.80–1.14 94 0.71**0.57–0.87
Chronic and unspeciﬁed bronchitis  14 1.99* 1.09–3.35 5 1.33 0.43–3.12 9 2.75**1.26–5.22 9 2.56* 1.17–4.87 5 1.42 0.46–3.33
(490–491)
Emphysema (492) 22 0.67 0.42–1.01 15 0.78 0.43–1.28 7 0.51 0.20–1.05 14 0.81 0.44–1.36 8 0.51 0.22–1.00
Digestive system diseases (520–579) 122 0.73**0.60–0.87 57 0.65**0.49–0.85 65 0.81 0.62–1.03 47 0.56**0.41–0.75 75 0.89 0.70–1.12
Cirrhosis of the liver (571) 60 0.74* 0.56–0.95 31 0.65* 0.44–0.93 29 0.87 0.58–1.24 25 0.59**0.38–0.87 35 0.90 0.63–1.25
Genitourinary system diseases  39 0.72* 0.51–0.98 12 0.52* 0.27–0.90 27 0.87 0.57–1.27 12 0.48**0.25–0.84 27 0.92 0.61–1.34
(580–629)
Accidents (E800–E949) 117 0.58**0.48–0.70 69 0.50**0.39–0.63 48 0.75 0.55–1.00 69 0.66**0.51–0.84 48 0.50**0.37–0.66
Suicide (E950–E978) 40 0.53**0.38–0.72 29 0.56**0.38–0.81 11 0.46**0.23–0.83 25 0.62* 0.40–0.91 15 0.43**0.24–0.71
Homicide (E960–E978) 9 0.33**0.15–0.62 6 0.31**0.11–0.68 3 0.37 0.08–1.07 4 0.28**0.08–0.72 5 0.38* 0.12–0.90
Other causes (residual codes) 67 0.72**0.55–0.91 31 0.67* 0.45–0.95 36 0.77 0.54–1.06 23 0.51**0.32–0.76 44 0.91 0.61–1.22
COD not obtained 143 95 48 72 71
Abbreviations: COD, cause of death; MN, malignant neoplasm; NA, not applicable; Obs, observed deaths. SMRs are based on U.S. referent rates.
aDeaths and person-years at-risk were accumulated during 1940–1998 for all outcomes except melanoma, NHL, and myeloma, which were accumulated during 1960–1998 due to rate ﬁle
restrictions. bOmitted categories include tuberculosis (3 deaths; ICD-9 codes 010–018), MN of other male genital organs (1 death; ICD-9 codes 186–187), skin and subcutaneous tissue
diseases (4 deaths; ICD-9 codes 680–709), musculoskeletal system and connective tissue diseases (8 deaths; ICD-9 codes 710–739), and symptoms and ill-deﬁned conditions (10 deaths;
ICD-9 codes 780–796, 798, and 799). *Two-sided p-value < 0.05. **Two-sided p-value < 0.01.Other than radiation and petrochemicals,
few occupational or environmental risk fac-
tors have been definitively associated with
risk of myeloma (American Cancer Society
2005). To our knowledge, this is the first
occupational cohort mortality study to report
an association between PCB exposure and
myeloma. The analyses provide suggestive
evidence that PCB exposure may have con-
tributed to the observed excess myeloma
mortality. 
Studies of neurologic effects among PCB-
exposed workers are limited. “Other nervous
system diseases” mortality was elevated
among cohort women, but without a trend
with cumulative exposure (results not shown).
We have analyzed speciﬁc neurodegenerative
diseases separately (Steenland et al. 2006). 
TCE exposure is considered a potential
confounder for liver cancer mortality (Hansen
et al. 2001; Motohashi et al. 1999) and possibly
for stomach and prostate cancer and myeloma
(Wartenberg et al. 2000). Supplemental analy-
ses excluding workers potentially exposed to
TCE were similar to those of the full cohort,
suggesting that observed excesses were not
related to known TCE exposure. 
The present study has the typical limita-
tions of occupational cohort mortality studies.
Possible exposure misclassiﬁcation cannot be
ruled out because PCB exposure was assessed
by job title, department, activities, and air
monitoring levels rather than with measured
congener-specific body burdens. The JEM
provided cumulative exposure scores for rela-
tive ranking of exposure histories. To reduce
possible exposure misclassification bias, we
limited exposure–response analyses to the
97% of workers with known job histories. 
Given our lack of information on non-
occupational risk factors, it is important to
consider whether the observed results could
be explained by regional differences in disease
burden, lifestyle, ethnicity, or potential expo-
sure to other cancer-causing chemicals. SMRs
based on U.S., state, and county rate ﬁles for
liver and prostate cancer and myeloma were
similar, and exposure–response relationships
with cumulative exposure were robust in sup-
plemental analyses. Therefore, findings are
not likely to be due to regional differences in
risk of these cancers. 
Smoking, alcohol use, and diet are poten-
tial risk factors for liver, intestinal, and stom-
ach cancers (Wingo et al. 2003) but have not
been consistently associated with prostate
cancer (Hickey et al. 2001; Platz et al. 2004)
or myeloma (Brown et al. 1997). The effect
of lifestyle factors on gastrointestinal cancers
is expected to be small because cohort mortal-
ity from other conditions associated with
lifestyle risks, such as heart and respiratory
diseases and cirrhosis of the liver, was less
than expected or as expected. 
Ethnic differences in cancer risk must be
considered because the ethnic composition of
the plant 2 workforce reﬂected demographics
of southeast Massachusetts, with a large
population of Cape Verdean and Portuguese
immigrants and their descendants (Brehm
et al. 2002). Cape Verde may share with the
rest of West Africa a substantial risk of liver
cancer, retained by ﬁrst generation emigrants
(London and McGlynn 1996; Parkin et al.
2003). Because most Cape Verdeans in this
cohort were U.S. born, their rates of stomach,
liver, and intestinal cancers likely would be
more similar to U.S. rates; there is some evi-
dence that cancer rates in second-generation
migrants resemble those in their adopted
country rather than in their native country
(Wingo et al. 2003). 
Possible misclassiﬁcation of ethnicity as a
factor in the observed excess liver cancer can-
not be directly evaluated because we have lim-
ited race-specific data. A sensitivity analysis
used Portuguese surnames as a surrogate for
Cape Verdean ethnicity, addressing whether
race could have been misclassified for Cape
Verdean workers. In analyses in which those
with Portuguese surnames were temporarily
coded as “nonwhite,” SMRs were similar to
those in the current analysis (results not
shown). 
Given the multiple outcomes examined,
significant positive associations could have
occurred by chance (Shields 2006). Positive
associations lacking exposure response are less
likely to be causal in nature and require further
corroboration. 
Prince et al.
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Table 3. Poisson regression results for cancer outcomes among PCB-exposed workers employed ≥90 days.a
Underlying cause of death, No lag 10-Year lag 20-Year lag
cumulative exposure (unit-years)b Obs RR 95% CI Obs RR 95% CI Obs RR 95% CI
All cancers
< 150 254 1 — 278 1 — 359 1 —
150–< 620  229 1.11 0.93–1.33 232 1.25 1.05–1.50 214 1.31 1.10–1.57
620–< 2,300 238 1.25 1.05–1.50 228 1.31 1.09–1.56 211 1.29 1.08–1.55
≥ 2,300 240 1.28 1.06–1.53 223 1.34 1.11–1.61 177 1.33 1.09–1.61
p = 0.030c p = 0.032 p = 0.061 
Stomach
< 150 5 1 — 7 1 — 10 1 —
150–< 620 6 1.50 0.46–4.91 5 1.39 0.43–4.52 9 3.50 1.23–9.96
620–< 2300 10 3.16 1.08–9.28 9 3.14 1.13–8.69 6 2.77 0.87–8.76
≥ 2,300 8 2.93 0.93–9.22 8 3.49 1.16–10.52 4 2.38 0.63–9.04
p = 0.12 p = 0.043 p = 0.62
Stomach (men)
< 150 3 1 — 4 1 — 7 1 —
150–< 620 5 2.09 0.50–8.76 4 1.97 0.47–8.14 7 4.33 1.26–14.90
620–< 2300 8 4.40 1.16–16.60 8 5.07 1.48–17.34 6 4.53 1.26–16.30
≥ 2,300 8 4.90 1.27–18.90 8 6.30 1.73–22.98 4 3.86 0.89–16.65
p = 0.039 p = 0.011 p = 0.32 
Intestine, excluding rectum
< 150 21 1 — 23 1 — 31 1 —
150–< 620 26 1.48 0.83–2.62 28 1.80 1.03–3.15 26 1.88 1.08–3.27
620–< 2300 26 1.47 0.82–2.63 26 1.62 0.91–2.89 26 1.74 0.99–3.05
≥ 2,300 27 1.44 0.80–2.59 23 1.41 0.77–2.59 17 1.34 0.70–2.53
p = 0.55 p = 0.87 p = 0.99 
Intestine, excluding rectum (women)
< 150 7 1 — 9 1 — 13 1 —
150–< 620 15 2.42 0.98–5.93 17 2.76 1.21–6.31 14 2.54 1.11–5.80
620–< 2300 19 2.65 1.10–6.39 16 2.19 0.94–5.12 20 3.04 1.38–6.71
≥ 2,300 20 2.82 1.16–6.86 19 2.75 1.18–6.42 14 2.63 1.11–6.24
p = 0.16 p = 0.18 p = 0.26
Rectum
< 150 5 1 — 5 1 — 7 1 —
150–< 620 5 1.13 0.33–3.93 5 1.24 0.36–4.30 3 0.76 0.20–2.98
620–< 2300 1 0.20 0.02–1.77 1 0.22 0.03–1.88 3 0.62 0.16–2.44
≥ 2,300 8 1.35 0.43–4.26 8 1.56 0.50–4.92 6 1.60 0.51–4.97
p = 0.36 p = 0.27 p = 0.26 
Biliary passages, liver, and gallbladder
< 150 2 1 — 4 1 — 6 1 —
150–< 620 3 1.72 0.29–10.33 2 0.75 0.14–4.20 1 0.44 0.05–3.89
620–< 2300 6 3.07 0.61–15.43 6 1.93 0.52–7.15 6 2.28 0.64–8.11
≥ 2,300 9 4.16 0.87–19.80 8 2.58 0.72–9.22 7 3.23 0.90–11.59
p = 0.071 p = 0.094 p = 0.039 
Breast
< 150 29 1 — 34 1 — 45 1 —
150–< 620 26 1.09 0.64–1.85 26 1.21 0.72–2.04 23 1.20 0.70–2.04
620–< 2300 19 0.79 0.44–1.43 15 0.68 0.36–1.27 15 0.75 0.41–1.40
≥ 2,300 27 1.32 0.75–2.30 26 1.44 0.82–2.52 18 1.25 0.68–2.30
p = 0.26 p = 0.17 p = 0.52
Continued, next pageSelection bias due to the healthy worker
effect, in conjunction with low statistical
power for certain causes of death, may have
reduced our ability to detect increases in mor-
tality caused by PCB exposure. However, the
healthy worker effect, associated with greatly
decreased heart disease mortality, is not strong
in this cohort, especially in plant 2 (Table 2),
and internal comparisons reduced healthy
worker selection effect (Richardson et al.
2004). Because 75% of workers left the plants
before the age of 55 years—presumably for
other jobs rather than retirement—we cannot
control for healthy worker survival by includ-
ing time since last employment in our models. 
The major strengths of the present study
include the large number of workers, the
59 years of follow-up, and the analysis of
mortality with estimated cumulative exposure.
The relatively high proportion of women
(> 50%) also provided a unique opportunity to
examine differential mortality risk by sex (Huff
2001) in relation to cumulative PCB exposure. 
The present study adds to the body of
knowledge regarding PCB-related health
effects and corroborates previous studies
showing an increase in mortality from liver
cancers; however, we cannot clearly associate
intestinal and rectal cancers with PCB expo-
sure. Melanoma mortality was moderately
elevated, especially in men and plant 1 work-
ers, but with no evidence of an exposure–
response relationship. 
To our knowledge, this is the ﬁrst occupa-
tional cohort study showing a strong exposure–
response relationship between cumulative PCB
exposure and mortality from prostate cancer. It
also provides suggestive evidence that excess
mortality risk from myeloma, stomach cancer
among men, and ovarian cancer may be asso-
ciated with long-term occupational exposure
to PCBs. 
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